The rigorous evaluation process undertaken by U.S. News & World Report examines nearly 100 hospitals with pediatric oncology programs annually, selecting the top 50 based on comprehensive clinical data and a broad survey of pediatric specialists. This meticulous assessment incorporates multiple parameters, including the availability of advanced clinical resources like bone marrow transplantation, specialized programs for brain tumors and sarcomas, and adherence to accreditation standards such as those set by the Foundation for the Accreditation of Cellular Therapy (FACT). Furthermore, performance metrics such as patient mortality rates, infection rates, and compliance with established best practices weigh heavily in the rankings, ensuring that only hospitals demonstrating superior clinical outcomes are recognized.

This recognition coincides closely with Forbes naming St. Jude as the No. 2 Best Employer for Healthcare Professionals in its recent 2025 survey. Such dual acknowledgment highlights the hospital’s unique culture where cutting-edge research and compassionate patient care are supported by a collaborative and forward-thinking workforce. The internal environment of the hospital plays a critical role in fostering innovation and excellence in treatment protocols, directly benefiting patients and their families.

Dr. Ellis J. Neufeld, the hospital’s executive vice president and clinical director, attributes this extraordinary success to the unwavering dedication and compassion of St. Jude’s clinical teams. Their continuous pursuit of excellence and breakthroughs in pediatric oncology fuels the hospital’s ability to pioneer new therapies and improve survival rates. The integration of scientific inquiry with clinical practice at St. Jude exemplifies a holistic approach that pushes the boundaries of traditional cancer treatment paradigms.

St. Jude uniquely operates as the only National Cancer Institute (NCI)-designated Comprehensive Cancer Center devoted exclusively to children. This designation reflects the hospital’s exceptional caliber, having received the highest possible “exceptional” rating in its last three NCI reviews. This elite status enables St. Jude to spearhead numerous groundbreaking clinical trials that are pivotal in developing novel treatment protocols and establishing new standards of care for pediatric cancer patients on a global scale.

At the forefront of translational medicine, Dr. Charles W.M. Roberts, St. Jude’s executive vice president and Cancer Center director, emphasizes the institution’s focus on accelerating scientific discovery and delivering transformative therapies. The convergence of scientists and clinicians propels advancements in next-generation interventions such as immunotherapy and precision medicine. Tailoring treatment regimens based on individual genetic and molecular profiles enhances therapeutic efficacy and minimizes long-term adverse effects, marking a paradigm shift in pediatric oncology.

The hospital’s programs have consistently demonstrated superior survival rates in some of the most challenging childhood malignancies, including acute lymphoblastic leukemia and medulloblastoma. These successes are the result of concentrated efforts within specialized cancer center programs and centers of excellence dedicated to leukemia, brain tumors, and immuno-oncology. Their collaborative, multidisciplinary approach enables comprehensive care models that address both immediate cancer treatment and long-term survivorship needs.

Central to advancing research, St. Jude leverages its Center of Excellence in Data-Driven Discovery along with the innovative St. Jude Cloud platform. These cutting-edge resources facilitate the sharing of extensive genomic datasets and promote international collaboration among researchers. Such open-access, data-driven frameworks are essential for uncovering the molecular underpinnings of pediatric cancers and expediting the development of targeted therapies, thereby accelerating breakthroughs on a global scale.

Hospital President and CEO Dr. James R. Downing credits the hospital’s sustained recognition to the extraordinary expertise, empathy, and perseverance of its workforce. Over the past year, St. Jude has made bold strides in scientific research, clinical care, and expanding its global footprint in pediatric cancer treatment. The overarching mission remains steadfast: to discover cures and provide hope to children suffering from devastating diseases, regardless of geography or socioeconomic status.

Beyond its clinical and research achievements, St. Jude’s distinctive model includes extensive partnerships with national and international institutions. These collaborations enable the hospital to conduct large-scale clinical trials and harmonize treatment approaches worldwide. Such cooperative efforts are vital in ensuring that advances in pediatric cancer therapies are widely accessible and rapidly implemented across diverse healthcare systems.

Moreover, the hospital continuously integrates emerging technologies such as machine learning and artificial intelligence into its research and diagnostic processes. These tools enhance the precision of disease classification, risk stratification, and predictive modeling, empowering clinicians to make more informed decisions. The synergy between technology and clinical expertise at St. Jude exemplifies the future landscape of pediatric cancer care.

Ultimately, the enduring excellence and leadership demonstrated by St. Jude Children’s Research Hospital underscore the profound impact that dedicated research, compassionate care, and innovative science can have on transforming the prognosis of children with cancer. As the institution advances toward new frontiers in oncology, its holistic approach continues to inspire hope and reshape the future of pediatric medicine.

Subject of Research: Pediatric Cancer and Oncology Research
Article Title: St. Jude Children’s Research Hospital Ranked Top 10 Pediatric Cancer Hospital for 18th Consecutive Year
News Publication Date: 2025
Web References:

• https://health.usnews.com/best-hospitals/pediatric-rankings/cancer
• https://www.forbes.com/sites/rachelpeachman/2025/09/25/meet-americas-best-employers-for-healthcare-professionals-2025/
• https://www.stjude.org/
• https://www.stjude.org/research/comprehensive-cancer-center.html
• https://www.stjude.org/research/centers-of-excellence.html
• https://www.stjude.org/research/departments/structural-biology/center-of-excellence-data-driven-discovery.html
• https://stjude.cloud/
  Image Credits: St. Jude Children’s Research Hospital
  Keywords: Pediatrics, Cancer patients, Oncology

In an unprecedented achievement, St. Jude Children’s Research Hospital has once again been honored with the coveted Magnet® designation by the American Nurses Credentialing Center (ANCC) for the third consecutive time. This year marks a significant milestone as the institution earned the prestigious Magnet with Distinction™ — an elite status reserved for the top one percent of hospitals nationwide. This recognition highlights St. Jude’s unwavering commitment to advancing nursing excellence and transforming patient outcomes through specialized care.

The ANCC Magnet Recognition Program stands as the gold standard for nursing quality, meticulously evaluating health care organizations on their nursing philosophy, leadership, patient care innovation, and adherence to nationally accepted benchmarks. The rigorous review process subjects hospitals to extensive interviews and comprehensive evaluations of nursing services, clinical effectiveness, and patient safety protocols. Achieving Magnet status requires hospitals to showcase superior nursing practices and cultural dedication to continual improvement in healthcare delivery.

This recent designation reaffirmed St. Jude’s position as a paragon of clinical nursing excellence, earning commendations across fourteen distinct domains of care — the highest number achieved by any Magnet hospital evaluated to date. Reviewers particularly praised the hospital’s investment in the professional growth and development of its nursing workforce. At St. Jude, over 90 percent of nurses maintain Bachelor of Science in Nursing (BSN) degrees, while more than 70 percent hold specialty certifications, underscoring the institution’s dedication to cultivating highly skilled nursing professionals.

Sarah Currie, MSN, RNC, NEA-BC, Chief Nursing Executive and Senior Vice President at St. Jude, expressed profound pride in this achievement, emphasizing how the Magnet with Distinction reflects the cumulative effort of a dedicated nursing team. She reiterated that this honor is a testament to the compassionate, evidence-based care delivered daily by St. Jude nurses, who collaborate seamlessly with interdisciplinary teams to provide extraordinary support to patients and families confronting devastating childhood illnesses.

Two nursing initiatives at the hospital were specifically recognized with “with Distinction” accolades, signaling targeted excellence in professional development and staff retention strategies. The Nurse Residency Program at St. Jude provides critical support for newly graduated nurses as they transition from academic study to clinical practice across inpatient and outpatient settings. This program has been integral in achieving record-low turnover rates among early-career nurses, fostering a robust, confident nursing workforce dedicated to pediatric oncology and hematology care.

Another remarkable achievement comes from the hospital’s Center of Advanced Practice Providers, a group comprising nurse practitioners, nurse anesthetists, and physician assistants. This cohort earned the ANCC Advanced Practice Transition to Practice Certification with Distinction, underscoring the high standards of advanced clinical practice fostered at St. Jude. The certification process evaluates expertise in complex clinical environments, ensuring these providers are equipped to deliver specialized, cutting-edge patient care.

Ellis Neufeld, MD, PhD, Clinical Director, Physician-in-Chief, and Executive Vice President at St. Jude, highlighted that attaining Magnet status for the third time, coupled with the inaugural “with Distinction” recognition, places the hospital firmly within the upper echelon of nursing excellence nationally. He applauded the nursing leadership and the entire clinical team for their commitment to delivering outstanding care, reinforcing St. Jude’s reputation as a leader in pediatric healthcare.

St. Jude’s journey with the Magnet program began in 2015 when it first earned the distinction, followed by a successful redesignation in 2020. The hospital diligently submits biannual progress reports and undergoes comprehensive reevaluation every four years to maintain this prestigious status. This ongoing commitment demonstrates a culture of relentless pursuit of clinical and organizational excellence, particularly in nursing practice standards.

James R. Downing, MD, President and CEO of St. Jude, acknowledged the collective effort behind this achievement, naming the nursing leadership team and clinical staff as key contributors to the hospital’s high-quality care. Dr. Downing emphasized that this recognition affirms St. Jude’s foundational goal: to make every day the best possible one for every patient and family the hospital serves, underpinned by exceptional clinical expertise and compassionate nursing care.

The ANCC, a subsidiary of the American Nurses Association, is the central certifying body for nursing board certification across the United States. It is recognized as the largest certifying authority for advanced practice registered nurses and operates one of the country’s longest-standing nursing certification programs. Their Magnet Recognition Program is internationally regarded for fostering nursing innovation, leadership, and data-driven quality improvements in healthcare.

Since its inception more than six decades ago, St. Jude Children’s Research Hospital has transformed the pediatric oncology and hematology landscape, pioneering research and clinical protocols that have increased childhood cancer survival rates from 20 to 80 percent. As the only National Cancer Institute-designated Comprehensive Cancer Center dedicated solely to children, St. Jude’s groundbreaking work continues to redefine care standards globally, ensuring children everywhere have access to the highest standard of specialized treatment.

This remarkable achievement in nursing excellence not only amplifies St. Jude’s commitment to superior patient care but also sets a powerful example across the healthcare spectrum. The hospital’s innovative nursing development programs, advanced practice certifications, and multidisciplinary collaboration exemplify a model of excellence that other institutions strive to emulate. St. Jude’s Magnet with Distinction status confirms that ongoing investment in nursing excellence is integral to clinical innovation and superior patient outcomes.

By intertwining expert clinical nursing practice with innovative support frameworks, St. Jude continues to elevate pediatric healthcare. This blend of scientific rigor, compassionate care, and leadership development fosters an environment where nurses thrive and patients receive transformative care. The Magnet with Distinction award truly honors this symbiotic relationship, recognizing the dedicated professionals who turn cutting-edge research into healing realities for children facing life-threatening illnesses.

As St. Jude Children’s Research Hospital advances toward future milestones, its Magnet recognition symbolizes not just the excellence of its nursing workforce but the holistic culture of care, innovation, and resilience that defines this world-class institution. This recognition will catalyze further advancements, ensuring that St. Jude remains at the forefront of pediatric clinical excellence, nurse development, and groundbreaking scientific discovery.

Subject of Research: Pediatric oncology, hematology, nursing excellence, clinical nursing practice

Article Title: St. Jude Children’s Research Hospital Achieves Historic Magnet with Distinction Recognition for Nursing Excellence

News Publication Date: Not specified in source

Web References:
– https://www.stjude.org/
– https://www.stjude.org/directory/c/sarah-currie.html
– https://www.stjude.org/directory/n/ellis-neufeld.html
– https://www.stjude.org/directory/d/james-downing.html

Image Credits: St. Jude Children’s Research Hospital

Keywords: Nursing, Oncology, Hematology, Pediatrics, Magnet Recognition, Advanced Practice Nurses, Clinical Excellence, Nurse Residency Program, Pediatric Cancer Care

Proteins are biological polymers composed of amino acids that fold into complex three-dimensional structures, critically influenced by their interaction with surrounding water molecules. These waters do not merely fill space; they participate actively in stabilizing the protein’s shape and modulating its biochemical activity. Particularly in drug discovery, where small molecules (ligands) are designed to bind specific protein sites to modulate function, knowing the exact location and behavior of water molecules is essential. Unfortunately, prevailing structural determination methods such as X-ray crystallography and cryo-electron microscopy operate at cryogenic temperatures, often distorting the natural positioning of water molecules due to freezing artifacts. This has led to an underappreciation and, in many cases, outright exclusion of water molecules in drug design efforts.

Recognizing this critical gap, Dr. Marcus Fischer and Dr. Justin Seffernick from St. Jude’s Department of Chemical Biology & Therapeutics developed ColdBrew, a computational algorithm that overcomes the limitations imposed by cryogenic structural data. Unlike conventional approaches, ColdBrew uses extensive protein water network data to calculate the likelihood of water molecule presence at physiological, higher temperatures. This correction allows researchers to better interpret experimental structures by distinguishing tightly bound, biologically relevant waters from those introduced artifactually by low-temperature data collection methods.

The heart of ColdBrew lies in its ability to predict water displacement probabilities within protein structures, a feature with profound implications for drug discovery. Proteins bind ligands by displacing water molecules from their binding sites, but not all waters are equal; some are so tightly bound that displacing them is energetically unfavorable, while others readily vacate, facilitating ligand binding. By quantitatively assessing the likelihood that specific water molecules remain present at binding sites under native conditions, ColdBrew provides medicinal chemists with actionable insights. This enables the rational design of ligands that either exploit stable water molecules to enhance binding affinity or target sites where water displacement would be favorable, thus optimizing drug efficacy and selectivity.

One of the remarkable achievements of this project is the creation of a comprehensive, publicly accessible database containing ColdBrew predictions. Leveraging over 100,000 protein structures from the Protein Data Bank, the team conducted analyses covering more than 46 million water molecules. This expansive dataset offers an unparalleled resource for researchers around the globe, allowing them to tap into detailed water displacement predictions without the need for extensive computational resources. By democratizing access to these insights, ColdBrew has the potential to catalyze a paradigm shift in structure-based drug design, reducing trial-and-error in ligand development.

Beyond its immediate utility in pharmaceutical sciences, ColdBrew offers a methodological advancement with broad applicability across structural biology. The algorithm’s capacity to correct for cryo-induced artifacts elevates the fidelity of protein models, thereby enhancing downstream computational studies including molecular dynamics simulations and virtual screening. Importantly, the team demonstrated that the algorithm performs best at protein-ligand interfaces, the critical regions of interest for drug development, ensuring that its impact is maximally relevant to therapeutic innovation.

At the conceptual level, ColdBrew underscores the complex thermodynamic interplay between proteins, water, and ligands—a subtle dance that governs molecular recognition. Water molecules, often dismissed as inconvenient noise in structural data, emerge as critical determinants of biochemical specificity and affinity. The algorithm’s predictive capacity thus illuminates the “hidden” water landscape, allowing scientists to factor in water-mediated interactions hitherto considered too challenging to characterize reliably.

Moreover, ColdBrew encourages a reevaluation of prevailing drug discovery strategies that frequently disregard water molecules due to the uncertainty of their positioning. These findings suggest that drug designers may have unknowingly avoided targeting binding sites with tightly bound water molecules, potentially missing opportunities for improved binding or altered pharmacodynamics. Armed with ColdBrew’s insights, the design process becomes more nuanced, balancing displacement and accommodation of water molecules to fine-tune ligand efficacy.

From a technical standpoint, developing ColdBrew involved sophisticated analysis of temperature-dependent protein-water interactions. The algorithm probabilistically models water occupancy based on structural data obtained under varying temperature regimes, integrating these with known principles of water thermodynamics and protein chemistry. This methodological innovation bridges experimental and computational fields, harnessing large-scale structural data to resolve a long-standing bottleneck in capturing the true aqueous environment of proteins.

Collaboration with the broader scientific community is a key aspect of the ColdBrew initiative. Recognizing the importance of open science, the researchers have made their predictions and underlying datasets accessible via a digital repository, facilitating integration with existing bioinformatics pipelines. This openness accelerates validation efforts, adoption, and iterative improvement of the tool as more data becomes available.

The pioneering work on ColdBrew was supported by funding from the National Institutes of Health and the American Lebanese Syrian Associated Charities, reflecting the vital interplay between basic science and translational research. Dr. Fischer and his team at St. Jude Children’s Research Hospital continue to push the boundaries of chemical biology, employing cutting-edge computational methods to unravel complexities that have long challenged researchers in the realm of protein structure and function.

In conclusion, the introduction of ColdBrew represents a transformative step in structural biology and drug discovery, addressing a crucial blind spot by bringing water molecules into sharper focus. As drug developers seek increasingly sophisticated ways to modulate biological targets, tools like ColdBrew that reveal the nuanced behavior of water will undoubtedly become indispensable. By redefining how researchers interpret protein structures, ColdBrew not only enhances molecular insight but also promises to accelerate the discovery of safer and more effective therapeutics.

Subject of Research: The role of water molecule dynamics in protein structures and their implications for drug discovery.

Article Title: ColdBrew: A Novel Algorithm for Accurate Water Displacement Predictions in Protein Structures Enhancing Drug Design.

News Publication Date: June 27, 2025.

Web References:
ColdBrew Data Repository
Fischer Lab at St. Jude
Department of Chemical Biology & Therapeutics
St. Jude Children’s Research Hospital

Image Credits: St. Jude Children’s Research Hospital

Keywords

Drug discovery, Water molecules, Protein structure, Protein-ligand binding, Cryogenic temperature artifacts, Computational biology, Structural biology, Protein Data Bank, Molecular dynamics, Chemical biology, ColdBrew algorithm, Thermodynamics

AML, a heterogeneous malignancy of the bone marrow, poses a dire clinical challenge, particularly in pediatric cases harboring chromosomal rearrangements involving the NUP98 gene. These rearrangements produce fusion proteins that hijack normal cellular machinery to activate cancer-driving genes, fostering disease progression and resistance to conventional chemotherapy. Until now, targeting such fusion-driven leukemias has been impeded by the dual obstacles of toxicity—owing to the essential functions of native proteins—and incomplete responses to existing agents like menin inhibitors.

The research team, spearheaded by senior co-corresponding author Dr. Charles Mullighan of St. Jude’s Department of Pathology, embarked on a systematic interrogation of the proteomic landscape associated with NUP98 fusion proteins in AML cell models. Employing cutting-edge genome editing technologies, they mapped protein interactions and conducted functional knockouts to delineate which molecular components the leukemia cells critically depend upon for survival. Their meticulous efforts pinpointed two histone acetyltransferases—MOZ/KAT6A and HBO1/KAT7—as integral constituents of a complex facilitating oncogene activation.

Histone acetyltransferases play pivotal roles in chromatin remodeling by adding acetyl groups to histones, thereby modulating gene accessibility and transcriptional activity. In leukemia driven by NUP98 fusions, the MOZ/KAT6A and HBO1/KAT7 complexes appear co-opted to maintain the aberrant expression of genes that sustain malignant transformation. By targeting these acetyltransferases, researchers hypothesized that it would be possible to dismantle the pathological gene expression networks essential for leukemia cell viability without the deleterious effects linked to direct inhibition of native proteins.

To validate this hypothesis, the investigators utilized pharmacologic inhibitors designed to disrupt the activity of the MOZ/KAT6A and HBO1/KAT7 complexes. Treatment with these inhibitors alone significantly improved survival outcomes in patient-derived AML mouse models. Yet, the most striking therapeutic benefit emerged when these agents were combined with menin inhibitors, which block menin, a protein that partners with NUP98 fusions to regulate leukemic gene expression. The combinatorial treatment demonstrated synergistic efficacy, markedly prolonging survival in preclinical models, including those simulating relapsed disease—a stage where therapeutic options are critically limited.

This dual-targeted approach exemplifies a precision medicine strategy that circumvents the limitations of single-agent therapy by simultaneously disarming multiple nodes of the oncogenic network. Dr. Mullighan emphasized the potential clinical implications, stating, “Our findings reveal a previously unrecognized molecular dependency in NUP98-rearranged AML and provide a robust rationale for clinical trials that evaluate the combination of menin inhibition with acetyltransferase complex disruption, particularly in patients who do not respond to menin inhibitors alone.”

The identification of MOZ/KAT6A and HBO1/KAT7 as druggable targets was accomplished through a comprehensive proteogenomic workflow, combining chromatin immunoprecipitation, mass spectrometry, and CRISPR-Cas9–mediated knockout screens. This integrated methodology enabled the researchers to not only map the physical interactome of NUP98 fusion proteins but also to functionally validate the essentiality of candidate proteins in maintaining leukemia cell survival.

Beyond providing mechanistic insights, the study showcased the therapeutic promise of acetyltransferase inhibition by utilizing small molecule compounds that selectively bind and inhibit MOZ/KAT6A and HBO1/KAT7 activity. These agents effectively disrupted the assembly of the oncogenic transcriptional complex, leading to downregulation of critical leukemogenic genes and impairment of leukemia cell proliferation and survival in vitro and in vivo.

Importantly, the combined therapy exhibited tolerability in animal models, indicating a potentially favorable therapeutic window. Given the aggressive nature of NUP98 fusion-driven AML and the limited efficacy of current treatments, these findings offer hope for overcoming one of the most pernicious obstacles in pediatric oncology.

The study was a collaborative effort involving a multidisciplinary team of scientists from premier institutions including St. Jude Children’s Research Hospital, Dana-Farber Cancer Institute, University of Cambridge, Washington University in St. Louis, and Memorial Sloan Kettering Cancer Center. Supported by extensive funding from the National Cancer Institute and various philanthropic organizations, this work underscores the power of collaborative translational research in moving promising laboratory discoveries toward clinical application.

As the landscape of leukemia treatment continues to evolve, this novel combination strategy targeting histone acetyltransferase complexes alongside menin inhibition could pave the way for new therapeutic regimens. Ongoing and future clinical trials will be essential to assess the safety, dosing, and efficacy of this approach in children afflicted by NUP98-rearranged AML, potentially transforming outcomes for a challenging patient population.

With over 80% of childhood cancer patients now surviving, thanks in part to relentless research and innovation at institutions like St. Jude, advances such as this herald a new era where even the most intractable leukemias can be confronted with targeted, rational therapies. This breakthrough not only illuminates the molecular underpinnings of AML pathogenesis but exemplifies how precision targeting of epigenetic regulators can arrest cancer progression and improve patient prognosis.

Subject of Research: Pediatric acute myeloid leukemia (AML) driven by NUP98 fusion proteins and therapeutic targeting of histone acetyltransferase complexes.

Article Title: KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia

News Publication Date: 19-Jun-2025

Web References:
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-1772/762972/KAT6A-and-KAT7-Histone-Acetyltransferase-Complexes

References:
DOI: 10.1158/2159-8290.CD-24-1772

Image Credits: St. Jude Children’s Research Hospital

Keywords: Pediatric AML, NUP98 fusion proteins, histone acetyltransferase, MOZ/KAT6A, HBO1/KAT7, menin inhibition, cancer genomics, epigenetic therapy, pediatric oncology, leukemia, gene expression, protein complexes

Dr. Finkel’s tenure at St. Jude symbolizes a crucial evolution in pediatric medicine. CENT represents the clinical wing of the Pediatric Translational Neuroscience Initiative (PTNI), an innovative research platform focused on turning laboratory discoveries into tangible clinical interventions for catastrophic neurological diseases. By integrating cutting-edge neuroscience with clinical application, CENT aims to address urgent unmet needs in pediatric neuromuscular disorders, including spinal muscular atrophy (SMA), Duchenne muscular dystrophy, inherited neuropathies, and neurometabolic disorders. This expansion aligns with St. Jude’s broader vision to extend its decades-long legacy of curing childhood cancer to crippling neurologic diseases.

Among Dr. Finkel’s most notable clinical achievements is his leadership in conducting the first in utero treatment of spinal muscular atrophy using risdiplam, an orally administered drug. SMA is a genetic neuromuscular disorder characterized by progressive muscle wasting and weakness due to the degeneration of motor neurons. Traditionally diagnosed postnatally, SMA results in severe disability or death if untreated. Dr. Finkel’s prenatal intervention represents a revolutionary paradigm shift in treatment, leveraging the prenatal environment’s unique immunological and developmental properties to arrest disease progression even before birth.

This landmark in utero treatment, performed in 2022, demonstrated remarkable efficacy. The infant treated prenatally with risdiplam showed no detectable manifestations of SMA over two years after birth, a stark contrast to the expected clinical trajectory of untreated SMA patients. The underlying mechanism involves risdiplam’s ability to increase the production of survival motor neuron (SMN) protein by modifying the splicing of the SMN2 gene, thereby compensating for the loss of function mutation in SMN1. Administering the therapy during fetal development maximizes the preservation of motor neuron populations before irreversible degeneration occurs, highlighting the critical window that prenatal therapy opens for neurodegenerative diseases.

Published in a letter to the New England Journal of Medicine in early 2025, these findings provide robust proof of concept for prenatal intervention as a viable therapeutic strategy. This study not only underscores the biological plausibility but also opens new investigative avenues for other genetic neuromuscular disorders traditionally treated postnatally or symptomatically. The clinical outcomes have profound implications for developmental neurobiology, pharmacokinetics in utero, and fetal immune tolerance mechanisms, which collectively influence the safety and efficacy of early pharmacological intervention.

Dr. James R. Downing, president and CEO of St. Jude Children’s Research Hospital, emphasized that Dr. Finkel’s designation as a TIME100 Health honoree illuminates the significance of pioneering pediatric neuromuscular diseases that have historically been underserved. His work encapsulates the hospital’s expanding commitment to eradicate not only life-threatening cancers but also the devastating neurological disorders that compromise childhood development and survival worldwide. This recognition amplifies ongoing efforts to develop therapies that provide durable, disease-modifying benefits, substantially improving quality of life for affected children.

The research implications of Dr. Finkel’s work extend beyond SMA into a broad spectrum of neurological diseases caused by genetic mutations, neurodegeneration, and metabolic imbalances. His extensive clinical practice focuses on optimizing therapeutics involving gene modulation, neurometabolic stabilization, and neuroprotective strategies. By combining clinical acumen with translational neuroscience, Dr. Finkel accelerates the bench-to-bedside pathway, enabling novel interventions to move rapidly through preclinical models to clinical trials and eventually standard of care.

Over his distinguished career, Dr. Finkel has authored more than 150 peer-reviewed articles and book chapters, reflecting his deep scientific insight and commitment to collaborative neurology research. He has played an instrumental role in designing innovative clinical trials that incorporate biomarkers, electrophysiological metrics, and advanced imaging to measure therapeutic efficacy objectively. His approach exemplifies precision medicine tailored to the unique genetic and phenotypic profiles of pediatric patients suffering from debilitating neuromuscular disorders.

The success of in utero therapy for SMA challenges existing paradigms of treatment timing and delivery, suggesting that early intervention—potentially initiated during gestation—could prevent irreversible neurological damage more effectively than postnatal treatments. This has profound implications for future drug development targeting other monogenic neurological conditions, advocating for the integration of prenatal diagnostic tools and therapeutic planning into neonatal care. This clinical innovation could dramatically shift global health policies around fetal medicine and pediatric neurology.

Dr. J. Paul Taylor, executive vice president and scientific director at St. Jude and director of PTNI, pointed out the critical unmet clinical need in catastrophic neurological diseases, areas where research has lagged behind oncology. Unlike cancer or sickle cell disease, many neurological disorders have lacked effective disease-modifying therapies. The translational neuroscience platform led by Dr. Finkel is transforming this landscape by combining molecular biology, genetics, and pharmacology to exploit new therapeutic targets and innovative delivery systems, including oral small molecules such as risdiplam.

St. Jude Children’s Research Hospital’s historic mission has evolved from groundbreaking pediatric oncology to embracing complex neurological diseases, leveraging its multidisciplinary expertise and infrastructure. The hospital remains a world leader in pediatric biomedical research, integrating genomic sequencing, cellular biology, and clinical trials to foster therapeutic development. By sharing discoveries openly with global collaborators, St. Jude ensures advances benefit children worldwide, supporting a collaborative, data-driven approach to medicine.

In conclusion, Dr. Richard S. Finkel’s recognition as a TIME100 Health honoree is a testament to his visionary leadership and translational impact in pediatric neurology. His achievements in prenatal treatment for SMA represent a transformative milestone that reshapes how we understand, diagnose, and treat genetic neuromuscular disorders. With ongoing clinical and scientific efforts, Dr. Finkel and the St. Jude team continue to push the boundaries of pediatric neurotherapeutics, offering hope and healing to children and families facing devastating neurological diseases.

Subject of Research: Pediatric Neuromuscular Disorders, Prenatal Therapy for Spinal Muscular Atrophy
Article Title: Richard S. Finkel Named to TIME100 Health 2025 for Pioneering Prenatal Treatment of Spinal Muscular Atrophy
News Publication Date: 2025
Web References:

• https://time.com/collections/time100-health-2025/7279665/richard-finkel-kelly-hennings/?filters=pioneers
• https://www.stjude.org/directory/f/richard-finkel.html
• https://www.stjude.org/research/initiatives/pediatric-translational-neuroscience-initiative.html
• https://www.stjude.org/care-treatment/treatment/neurological-disorders/spinal-muscular-atrophy.html
• https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/promising-results-from-first-prenatal-therapy-for-spinal-muscular-atrophy.html

Image Credits: St. Jude Children’s Research Hospital

Keywords: Spinal muscular atrophy, Neurology, Neurological disorders, Pediatrics, Neuropathology

Since its inception in 2024, the Damon Runyon-St. Jude Pediatric Cancer Research Fellowship has emerged as a crucial lifeline for ambitious scientists pursuing novel solutions to the complications inherent in treating children’s cancer. The initiative was established specifically to fill a glaring funding gap, which often compels elite researchers to divert their talents toward more prevalent adult cancer studies or lucrative roles in the pharmaceutical industry. This fellowship aims to redirect focus and resources back to the pressing needs in pediatric cancer research, fostering an environment where collaboration and innovation can flourish.

Under the leadership of prestigious field experts, a selection committee comprised of luminaries in pediatric oncology carefully scrutinizes candidates. These rigorous evaluations ensure that only the most talented and visionary researchers will receive this fellowship. Dr. James R. Downing, CEO and president of St. Jude, highlighted the partnership’s purpose, emphasizing its role in propelling researchers toward groundbreaking developments that could change the paradigm of childhood cancer therapy and management. The advancements achieved through this fellowship will contribute significantly to fulfilling St. Jude’s mission of curing and saving children across the globe.

One of the notable areas of research being tackled by the fellows revolves around diffuse midline gliomas (DMG). These pediatric brain tumors represent a critical challenge in oncology, known for their uniform lethality and resistance to current treatments. Dr. Ian Blumenthal, teaming up with Jim M. Olson, aims to pioneer new immune cell engagers capable of prompting a patient’s immune system to combat these tumors. His project focuses on leveraging the inherent variability of DMGs while preserving healthy tissue, which could result in treatments that not only enhance efficacy against pediatric gliomas but also advance the field of immunotherapy overall.

Fellow Matthew Decker is tackling acute myeloid leukemia (AML), a notoriously challenging form of cancer to cure among children. Current therapies are often fraught with harsh side effects that leave survivors vulnerable to long-term health complications. Dr. Decker’s innovative approach involves disrupting the N-Ras protein, a common mutation in pediatric AML, which could potentially sensitize cancer cells to existing treatments. His findings could usher in a new wave of therapies that prioritize patient well-being and minimize the toxic impact of conventional treatments.

Dr. Oriana Miltiadous is delving into the intricate relationship between the gut microbiome and immune responses in children undergoing allogeneic hematopoietic cell transplantation (allo-HCT). While allo-HCT can be life-saving for aggressive cancers like leukemia, it often triggers dangerous complications. By investigating the role of bile acids produced by gut microbiota, she hopes to identify methods for balancing immune responses, preventing inflammation, and ultimately enhancing recovery rates in young patients. Her work promises to yield transformative insights into the developing field of microbial influences on cancer therapy.

In a further inquiry into immune mechanisms, Dr. Geoffrey Smith is set to explore why immunotherapies have been largely ineffective in treating pediatric solid tumors such as osteosarcoma—the most common bone cancer in children. Utilizing a novel mouse model that replicates human osteosarcoma while retaining an intact immune system, Dr. Smith’s research aims to unveil barriers that hinder immune system activation against these tumors. His insights could lead to the design of more targeted immunotherapies that have the potential to dramatically alter patient outcomes in this challenging area of pediatric oncology.

Dr. Lara Wahlster’s research targets the developmental origins of acute lymphoblastic leukemia (ALL), the leading cause of cancer-related deaths in children. By applying advanced genomic techniques, she aims to uncover the biological processes that predispose children to blood cancers, providing a foundation for understanding the mechanisms at play. Her work is anticipated to yield novel therapeutic strategies that are informed by the genetic underpinnings of ALL, ultimately fostering advancements in treatment paradigms.

Fellow Tuyu Zheng is addressing ependymoma, a particularly aggressive brain tumor that proves challenging to manage in pediatric populations. Researching the interactions between tumor cells and healthy neurons, Dr. Zheng aims to map out how neuronal environments contribute to the growth of ependymomas. Her findings could pave the way for groundbreaking interventions and treatment strategies tailored to combat these resilient tumors, transforming care methodologies and improving prognoses.

Each of these pioneering research projects signifies a commitment to propelling pediatric cancer research into uncharted territories. By equipping the next generation of scientists with the necessary resources and support, the Damon Runyon-St. Jude fellowship is laying the groundwork for future advances. As these young researchers embark on their journeys to unravel the complexities of childhood cancers, their work holds the promise of substantially improving treatment options and transforming patient care.

The establishment of this fellowship illustrates a broader movement within the scientific community aimed at elevating the profile of pediatric cancer research. As adults have long dominated the funding landscape due to the prevalence of their diseases, the spotlight now turns to the urgent needs of children battling cancer. The acknowledgment of this gap and the proactive measures taken to address it through the Damon Runyon-St. Jude fellowship reflect a growing recognition of the unique challenges faced by pediatric patients.

Such initiatives not only optimize funding opportunities but also inspire a collaborative spirit among scientists, medical professionals, and institutions dedicated to fighting childhood cancer. The fellowship embodies the idea that holding our commitments to the youngest members of society can yield impactful results and foster an environment ripe for scientific inquiry. With commitment and collaboration, the future of pediatric cancer research appears promising, as these fellows step forward to illuminate new pathways in the pursuit of cures.

Through this fellowship’s collaborative initiatives, significant strides can be made in pediatric cancer treatment options, showcasing the importance of investment in specialized research. The efforts of fellows like Dr. Blumenthal, Dr. Decker, Dr. Miltiadous, Dr. Smith, Dr. Wahlster, and Dr. Zheng exemplify the dedication to addressing the nuances of pediatric cancer, ensuring that future generations may not only survive these diseases but also thrive beyond them.

As media outlets spread awareness of this groundbreaking fellowship, the hope is that more institutions will recognize the critical importance of pediatric cancer research. By fostering talent and providing financial support for innovative projects, we can pave the way for a transformative revolution in the quality and efficacy of treatments available for young patients.

Subject of Research: Pediatric Cancer Research Fellowship
Article Title: Transformative Research Initiatives in Pediatric Oncology
News Publication Date: February 13, 2025
Web References: Damon Runyon Cancer Research Foundation, St. Jude Children’s Research Hospital
References: None
Image Credits: Damon Runyon Cancer Research Foundation and St. Jude Children’s Research Hospital

Keywords: Pediatric cancer research, immunotherapy, leukemia, research fellowship, childhood cancer, ependymoma, gut microbiome, innovative treatments.

Hillman’s appointment is rooted in her remarkable history as a pioneer in the field of imaging. She holds an impressive track record in developing high-speed microscopes and advanced in-vivo imaging systems for studying living tissues. Under her leadership, a range of talented faculty members is expected to join the department, collectively driving the advancement of imaging techniques that span from microscopic imaging at the sub-cellular scale to comprehensive medical imaging processes. This diverse expertise will ideally enhance scientific studies while simultaneously improving patient care outcomes.

The establishment of this department is a clear indication of St. Jude’s commitment to innovation in biomedical research, especially focused on children. “Elizabeth is a renowned physicist, gifted biomedical engineer, and prolific inventor of new technologies,” remarked James R. Downing, MD, the president and CEO of St. Jude Children’s Research Hospital. The ambitious vision involves not merely building a functional department but rather creating a hub of excellence that integrates cutting-edge imaging technology into multidisciplinary research and clinical applications for children experiencing severe health challenges.

One of the primary objectives of this new department will be to develop and refine imaging and measurement methodologies that can facilitate transformative scientific studies. By leveraging advanced imaging technologies, researchers will likely better grasp disease processes and treatment outcomes, creating pathways for groundbreaking innovations in patient care. Hillman’s deep-rooted beliefs regarding the synergy between environment and innovation underscore the importance of St. Jude’s unique collaborative landscape. She acknowledges that local collaborations and shared scientific inquiries have significantly influenced her creative endeavors throughout her career.

Prior to joining St. Jude, Hillman made remarkable contributions during her tenure at Columbia University, serving as both a Herbert and Florence Irving Professor and a tenured professor in biomedical engineering and radiology. Her extensive 20-year career is marked by the successful development and application of a wide array of novel imaging and data analysis methods. These methods have not only advanced scientific inquiry but have also paved the way for potential commercial applications, evidenced by technologies she developed that have been licensed to major industry players like PerkinElmer and Leica Microsystems.

The broader implications of Hillman’s appointment extend beyond mere technological advancements. J. Paul Taylor, MD, PhD, St. Jude’s executive vice president and scientific director, articulated the revolutionary potential of recent advances in visualization and quantification methodologies. This revolutionary potential is expected to catalyze significant improvements in biomedical research specifically tailored to combating childhood diseases. Therefore, St. Jude’s commitment to propelling the institution forward in biomedical imaging innovation could manifest profound benefits for children diagnosed with life-threatening illnesses.

As Hillman transitions into her new role, she emphasizes the unique combination of talent and passion present at St. Jude, which she considers to be critical in addressing some of the most challenging questions in child health. The hospital’s environment presents a stimulating atmosphere where facilitators of scientific discovery can collaborate toward shared goals, maximizing the impact of their findings in real-time patient care. Hillman asserts that working in an inspiring environment like St. Jude will foster creativity and significantly heighten the immediate impacts of innovative discoveries.

Hillman’s academic pedigree includes a PhD in medical physics and bioengineering from University College London, one of the leading institutions known for driving scientific advancements. Furthermore, her post-doctoral work at the Martinos Center for Biomedical Engineering, affiliated with Massachusetts General Hospital and Harvard Medical School, provided her with foundational expertise in biomedical engineering, focusing on imaging sciences. She has authored over 100 research papers featured in esteemed journals such as Science, Nature Methods, Nature Photonics, and Nature Biomedical Engineering, showcasing her prominent role in advancing the field.

Moreover, Hillman has made substantial contributions to augmenting the scientific community’s understanding of critical biological processes and disease mechanisms. Her work reflects a synthesis of theory and applied sciences, which illustrates the value of interdisciplinary collaboration in driving biomedical progress. As a testament to her innovative contributions, she holds over 20 issued patents and was elected to the National Academy of Inventors in 2022. This remarkable recognition underscores her dedication to fostering an environment rich in innovation and invention, ensuring young researchers also have the opportunities to thrive within this dynamic landscape.

St. Jude Children’s Research Hospital has solidified its position as a preeminent institution in transforming how childhood diseases are understood, treated, and cured. With a unique focus as the only National Cancer Institute-designated Comprehensive Cancer Center exclusively dedicated to children, the hospital has played a critical role in improving pediatric treatment outcomes over its 60-plus-year history. Specifically, the treatment advancements achieved at St. Jude have propelled the childhood cancer survival rate from a mere 20% to 80%, representing a drastic shift and a beacon of hope for countless families across the globe.

Notably, the breakthroughs generated at St. Jude do not remain confined within its walls. The institution is deeply committed to sharing its discoveries, allowing healthcare providers worldwide to enhance treatment quality and care for children suffering from life-threatening conditions. Whether through its digital platforms or social media presence, St. Jude actively engages in disseminating vital knowledge that can have a lasting influence on partners in the healthcare community.

As the new Department of Imaging Sciences embarks on its groundbreaking journey under Hillman’s leadership, it signifies not just a commitment to scientific advancement but also a profound dedication to the lives of the children it serves. By uniting cutting-edge technology with a comprehensive understanding of pediatric diseases, the collaborative efforts within this department could redefine the contours of research excellence at the intersection of imaging and healthcare, ultimately transforming the future landscape of pediatric medicine for generations to come.

Subject of Research: Imaging and Measurement Approaches in Pediatric Medicine
Article Title: Elizabeth Hillman Appointed Founding Chair of St. Jude’s Imaging Sciences Department
News Publication Date: October 2023
Web References: St. Jude Children’s Research Hospital
References: N/A
Image Credits: Credit: St. Jude Children’s Research Hospital

Keywords

Imaging, Biomedical Engineering, Pediatric Medicine, High-Speed Microscopy, In-Vivo Imaging, Technology Innovation, Scientific Research, Child Health Care, Imaging Sciences, Medical Imaging.